EGEric M. Gnall

Eric M. Gnall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric M. Gnall has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Snorkel Stenting During Transcatheter Aortic Valve Implantation: A Single-Center Study

    by Massimo Baudo, Serge Sicouri, Yoshiyuki Yamashita, Dimitrios E. Magouliotis, Francesco Cabrucci, Sarah M. Carnila, Scott M. Goldman, Eric M. Gnall, William A. Gray, Sandro Gelsomino, et al.

    Background and Objectives: Coronary obstruction (CO) is a potentially fatal complication that can occur during transcatheter aortic valve implantation (TAVI). The snorkel stenting technique was developed to mitigate the risk of CO. The aim of the current study was to evaluate the safety and clinical outcomes of snorkel stenting in patients at high risk of developing CO. Materials and Methods: All patients undergoing TAVI with snorkel stenting between January 2018 and December 2023 were retrospectively included. The primary outcome was the evaluation of perioperative CO and myocardial infarction (MI) at follow-up. Results: Between 2018 and 2023, a total of 1476 TAVI procedures were conducted, with 21 patients undergoing snorkel stenting for CO prevention. Median STS was 5.0 [IQR 3.0–8.0]. Four patients (19.0%) had a history of prior percutaneous coronary intervention, and 85.7% (n = 18) had a degenerated bioprosthesis. Preoperative multidetector CT revealed a mean sinus of Valsalva diameter of 24.6 ± 6.8 mm and a mean annulus area of 402.0 ± 59.7 mm2. The mean heights of the left and right coronary ostia were 7.9 ± 3.3 mm and 10.6 ± 5.5 mm, respectively. Nine patients (42.9%) presented with severe aortic regurgitation. Snorkel stenting was performed on the left main coronary in nine cases, on the right coronary in 10 cases, and on both the left main and right coronary arteries in two cases. No procedural complications were observed. Postoperatively, there were no MIs; one patient suffered from a disabling stroke, and another patient required a new pacemaker implant. Thirty-day mortality rate was 0%. At a median follow-up of 1.25 years (IQR: 1.05–3.05), there were five rehospitalizations for heart failure, no aortic valve reinterventions, one disabling stroke (sub-acute), and one MI. Overall, four patients died, including two cardiovascular-related deaths. Conclusions: Snorkel stenting should be considered for selected high- or prohibitive-surgical-risk patients undergoing TAVI who are at increased risk of developing CO. This technique showed favorable procedural outcomes for preventing CO occurring during or in the perioperative period of TAVI procedures. The abstract of the present study was accepted for oral presentation at the New York Valves on 26 June 2025.


  • Open Access

    Evolution of Untreated Moderate Mitral Regurgitation After Transcatheter Aortic Valve Implantation

    by Massimo Baudo, Serge Sicouri, Francesco Cabrucci, Yoshiyuki Yamashita, Dimitrios E. Magouliotis, Sarah M. Carnila, Sandra V. Abramson, Katie M. Hawthorne, Harish Jarrett, Roberto Rodriguez, et al.

    Background and Objectives: Associated mitral regurgitation (MR) is frequently observed during transcatheter aortic valve implantation (TAVI). The progression of moderate MR remains undetermined, given uncertain clinical significance and natural history. This study aims to assess the evolution of moderate MR following TAVI. Materials and Methods: Between 2018 and 2023, 1476 patients underwent TAVI. We excluded those with previous aortic or mitral valve interventions, endocarditis, concomitant percutaneous coronary intervention, or emergent procedures. Patients with severe aortic or tricuspid regurgitation or significant mitral stenosis were excluded. Ultimately, only patients with moderate MR were included, resulting in a final population of 154 patients. Results: Mean age was 81.4 ± 7.8 years, 48.1% (74/154) were female, and 48.1% (74/154) were functional MR. There was one surgical conversion due to annular rupture. Thirty-day mortality was 1.9% (3/154). Postoperative echocardiography showed 38 (24.7%) patients with none/trace MR, 91 (59.1%) with mild MR, 22 (14.3%) with moderate MR, and 3 (1.9%) with severe MR. Finally, according to the echocardiographic follow-up [median follow-up 1.0 (IQR: 0.1–1.2) years], 20.1% (31/154) had no/trace MR, 39.6% (61/154) had mild MR, 35.7% (55/154) had moderate MR, and 4.5% (7/154) had severe MR. Overall, 67 (43.5%) patients had any MR grade progression, 62 (40.3%) had stable disease, and 25 (16.2%) had any MR grade reduction at the last follow-up from the operation. No difference in MR evolution was seen between functional and primary MR. Conclusions: Concomitant moderate MR during TAVI has a variable evolution over time. A more detailed characterization of patients with preoperative moderate MR undergoing TAVI is necessary to identify those with a disease progression risk.


  • Open Access

    Clinical Outcomes and Cost Analysis in Patients with Heart Failure Undergoing Transcatheter Edge-to-Edge Repair for Mitral Valve Regurgitation

    by Aleksander Dokollari, Serge Sicouri, Roberto Rodriguez, Eric Gnall, Paul Coady, Farah Mahmud, Stephanie Kjelstrom, Georgia Montone, Yoshiyuki Yamashita, Jarrett Harish, et al.

    Objective: To analyze the clinical and cost outcomes of transcatheter edge-to-edge repair (TEER) for mitral regurgitation (MR) in heart failure (HF) patients. Methods: All 162 HF patients undergoing TEER for MR between January 2019 and March 2023 were included. A propensity-adjusted analysis was used to compare 32 systolic vs. 97 diastolic vs. 33 mixed (systolic + diastolic) HF patients. Systolic, diastolic, and mixed HF patients were defined according to AHA guidelines. The primary outcome was the long-term incidence of all-cause death and major adverse cardiovascular and cerebrovascular events (MACCEs, all-cause mortality + stroke + myocardial infarction + repeat intervention). Results: The mean age was 76.3 vs. 80.9 vs. 76 years old, and the mean ejection fraction (EF) was 39.5% vs. 59.8% vs. 39.7% in systolic vs. diastolic vs. mixed HF, respectively. Postoperatively, the diastolic vs. systolic HF group had a higher intensive care unit stay (21 vs. 0 h; HR 67.5 (23.7, 111.4)]; lower ventilation time [2 vs. 2.3 h; HR 49.4 (8.6, 90.2)]; lower EF [38% vs. 58.5%; HR 9.9 (3.7, 16.1)]. In addition, the diastolic vs. mixed HF groups had a lower incidence of EF < 50% (11 vs. 27 patients; HR 6.6 (1.6, 27.3) and a lower use of dialysis (one vs. three patients; HR 18.1 (1.1, 287.3), respectively. At a mean 1.6 years follow-up, all-cause death [HR 39.8 (26.2, 60.5)], MACCEs [HR 50.3 (33.7–75.1)], and new pacemaker implantations [HR 17.3 (8.7, 34.6)] were higher in the mixed group. There was no significant total hospital cost difference among the systolic (USD 106,859) vs. diastolic (USD 91,731) vs. mixed (USD 120,522) HF groups (p = 0.08). Conclusions: TEER for MR evidenced the worst postoperative and follow-up clinical outcomes in the mixed HF group compared to diastolic and systolic HF groups. No total hospital cost differences were observed.

  • Open Access

    Mechanical Support in High-Risk Pulmonary Embolism: Review Article

    by Amer N. Kadri, Razan Alrawashdeh, Mohamad K. Soufi, Adam J. Elder, Zachary Elder, Tamam Mohamad, Eric Gnall, Mahir Elder

    Acute pulmonary embolism (PE) may manifest with mild nonspecific symptoms or progress to a more severe hemodynamic collapse and sudden cardiac arrest. A substantial thrombotic burden can precipitate sudden right ventricular strain and failure. Traditionally, systemic thrombolytics have been employed in such scenarios; however, patients often present with contraindications, or these interventions may prove ineffective. Outcomes for this medically complex patient population are unfavorable, necessitating a compelling argument for advanced therapeutic modalities or alternative approaches. Moreover, patients frequently experience complications beyond hemodynamic instability, such as profound hypoxia and multiorgan failure, necessitating assertive early interventions to avert catastrophic consequences. The existing data on the utilization of mechanical circulatory support (MCS) devices are not exhaustive. Various options for percutaneous MCS devices exist, each possessing distinct advantages and disadvantages. There is an imminent imperative to develop a tailored approach for this high-risk patient cohort to enhance their overall outcomes.


  • Feasibility and outcomes with subclavian vein access for crescent jugular dual lumen catheter for venovenous extracorporeal membrane oxygenation in COVID-19 related acute respiratory distress syndrome

    by Sehrish Memon, Maria Eleni Drosou, Mara Caroline, Elena Casanova, Eric M Gnall

    Introduction: Femoral-femoral Veno-Venous ExtraCorporeal Life Support (V-V ECLS) has been associated with higher infections rates, vascular site bleeding complications, and restricted patient mobility. Jugular or bicaval dual lumen V-V ECLS conceptually overcomes some of these adverse factors, but experience has shown that jugular vein cannulation still limits mobility and has increased bleeding complications. Technique and outcomes of subclavian vein single-cannulation with Crescent jugular dual-lumen V-V ECLS is described. Method: five patients with COVID-19 related acute respiratory distress syndrome (ARDS) underwent right subclavian vein V-V ECLS placement with the Crescent 32 French jugular dual-lumen V-V ECLS catheter. A standardized percutaneous technique was developed that allowed efficient insertion without need for any specialized imaging (i.e. transesophageal echocardiogram) and outcomes assessed. Results: Mean age of the five patients was 41.2 years, all obese with an average basal mass index of 45.2 kg/m2 and mean days to decannulation of 24.2 days. Outcomes discovered included; improved patient mobility allowing physical rehabilitation, no vascular access site related complications requiring surgery or endovascular intervention, and none had evidence of superior vena cava syndrome. One patient had subclavian/axillary vein thrombosis with resolution after 3 months of direct-acting oral anticoagulants, and one patient had blood cultures positive at day 37, nearing decannulation. Conclusion: Subclavian vein access for crescent jugular dual lumen V-V ECLS catheter appears to be safe and feasible with added benefits of decreased bleeding and increased mobility over jugular or femoral-femoral access site for long term V-V ECLS support in COVID-19 related ARDS patients.